



image

1631✓

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: DEX-0255  
Inventors: Sun et al.  
Serial No.: 10/016,634  
Filing Date: 31 October 2001  
Examiner: Michael L. Borin  
Group Art Unit: 1631  
Title: Compositions and Methods Relating  
to Colon Specific Genes and  
Proteins

I, Nathan P. Letts, Registration No. 36,581, certify that this correspondence is being depositing with the U.S. Postal Service as First Class mail in an envelope addressed to the Assistant Commissioner for Patents and Trademarks, Washington, D.C. 20231.

On this date: 15 October 2003

Nathan P. Letts, Registration No. 36,581

Assistant Commissioner for Patents  
Washington, DC 20231

Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

(XX) In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the

date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, no additional fee is required.

( ) In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, therefore:

( ) Certification in Accordance with §1.97(e) is set forth below; or

( ) The US Patent Office is hereby authorized to charge the fee of \$180.00 as set forth in §1.17(p) to Deposit Account No. 50-0434.

( ) In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee, therefore included are: Certification in Accordance with §1.97(e); Petition Requesting Consideration of the Information Disclosure Statement; and the fee of \$130.00 as set forth in §1.17(i)(1).


(**XX**) Copies of each of the references listed on the attached Form PTO-1449 (modified) are enclosed herewith.

(**XX**) A copy of the PCT Search Report for PCT/US01/48414 which corresponds to the subject US application 10/016,634 is included.

- ( ) In accordance with §1.98(d), copies of some or all of the references listed on the attached Form PTO-1449 (modified) are not enclosed herewith because they were previously submitted to the U.S. Patent and Trademark Office in prior application Serial No. \_\_\_\_\_, filed \_\_\_\_\_, for which a claim for priority under 35 U.S.C. §120 has been made in the instant application.
- ( ) Due to the large size of some references, only relevant portions have been submitted. The included portions are as follows: @@ (@@). Full text of abbreviated reference is available if requested.
- ( ) Reference @@ is in a foreign language and only the front page was available. Therefore, a Geneseq Patent search report is attached to demonstrate relevance.
- (~~xx~~) All listed references are in the English language.

Please charge any deficiency or credit any overpayment to Deposit Account No. 50-0434. This form is submitted in duplicate.

Respectfully submitted,




Nathan P. Letts

Registration No. 36,581

Date: 15 October 2003

DiaDexus, Inc.  
343 Oyster Point Blvd.  
South San Francisco, CA 94080  
(650) 246-6400



Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 1

Serial Number	10/016,634
Filing Date	31 October 2001
Applicant	Sun et al.
Group Art Unit	1631
Examiner Name	Michael L. Borin
Attorney Docket Number	DEX-0255

**U.S. PATENT DOCUMENTS**

Examiner Initials *	Cite No.	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Class	Subclass

**FOREIGN PATENT DOCUMENTS**

Examiner Initials *	Cite No.	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Class	Subclass	Translation/ Comments
	AA	WO 02/077234 A2	10-03-2002	Sun et al.			

**OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No.	Author, title of the article, title of the item, date, volume-issue number, page(s).	Translation/ Comments
	AB	Bi, Weimin et al. Genes in a refined Smith-Magenis syndrome critical deletion interval on chromosome 17p11.2 and the syntenic region of the mouse. Genome Res. 2002 May;12(5):713-28.	
	AC	No Authors, The Sanger Center, Toward a complete human genome sequence. Genome Res. 1998 Nov;8(11):1097-108.	
	AD	Database Genebank, Accession No. NM_025051, Kawakami et al., Homo sapiens hypothetical protein FLJ23022 (FLJ23022), mRNA, 18 March 2001, see sequence.	
	AE	Database Genebank, Accession No. NP_079327, Kawakami et al., hypothetical protein FLJ23022 [Homo sapiens]., 18 March 2001, see sequence.	
	AF	Database Genebank, Accession No. AK026675, Sugano et al., Homo sapiens cDNA: FLJ23022 fis, clone LNG01117, 29 September 2000, see sequence.	
	AG	Database Genebank, Accession No. NG_000940, Rogers et al., Homo sapiens psihHbB hair keratin pseudogene (KRTHBP2) on chromosome 12, 10 April 2002, see sequence.	
	AH	Database Genebank, Accession No. NM_170743, Gallagher et al., Homo sapiens interleukin 28 receptor, alpha (interferon, lambda receptor) (IL28RA), transcript variant 1, mRNA., 15 November 2002, see sequence.	
	AI	Database Genebank, Accession No. NM_003929, Shimizu et al., Homo sapiens RAB7, member RAS oncogene family-like 1 (RAB7L1), mRNA, 19 March 1999, see sequence.	

Examiner  
SignatureDate  
Considered

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.